Hansa’s enzyme therapy flunks Phase 3 trial in rare kidney disease

Hansa Biopharma said Tuesday that its IgG-targeting treatment candidate has failed a late-stage study in a rare type of kidney disease due to an overperforming control arm. The Swedish biotech’s imlifidase plus standard of care ...